ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Pharmacokinetics"

  • 2021 American Transplant Congress

    Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients

    A. Demirag1, P. L. Lobo2, J. Oberholzer1, A. Kumar2, B. Rawashdeh1, S. L. Lennon1, H. N. Guvener Demirag1, A. Doyle2, J. Geystone3, K. L. Brayman1

    1Transplantation, University of Virginia Medical Center, Charlottesville, VA, 2Transplantation Nephrology, University of Virginia Medical Center, Charlottesville, VA, 3Clinical Pharmacy, University of Virginia Medical Center, Charlottesville, VA

    *Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…
  • 2021 American Transplant Congress

    De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience

    N. Singh1, T. Le1, M. S. Naseer1, S. Asmil1, A. Palermini1, A. Qamar1, R. Chand1, S. Tandukar1, D. Aultman2, H. Shokouh-Amiri2, G. Zibari2

    1Transplant, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA, 2Advanced Surgery, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA

    *Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…
  • 2021 American Transplant Congress

    Elexacaftor/ivacaftor/tezacaftor in Lung Transplant Recipients: A Case Series

    L. M. Potter1, B. Vargas2, S. M. Rotolo1, C. McEwen1, K. Tsui1

    1University of Chicago Medicine, Chicago, IL, 2Roosevelt University, Chicago, IL

    *Purpose: Little data is published describing the safety or efficacy of elexacaftor/ivacaftor/tezacaftor in lung transplant recipients. Even though it is not expected to offer pulmonary…
  • 2021 American Transplant Congress

    The Impact of De Novo Dose-Adjustment Strategies with Tacrolimus XR (LCP-Tac) in Kidney Transplant Recipients

    T. Carcella, F. Bartlett, N. Patel, V. Rohan, D. Taber

    Medical University of South Carolina, Charleston, SC

    *Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for the prophylaxis of rejection in de novo kidney transplant recipients. It provides less variable…
  • 2021 American Transplant Congress

    Managing the Significant Drug-Drug Interaction Between Tacrolimus and Letermovir in Solid Organ Transplant Recipients

    J. Hedvat, J. Choe, D. Salerno, J. Scheffert, D. Bley, A. Anamisis, T. Shertel, J. Lee, E. Liu, N. W. Lange

    NewYork-Presbyterian Hospital, New York, NY

    *Purpose: Letermovir does not appear to share cross-resistance with ganciclovir and is not associated with nephrotoxicity or myelosuppressive effects, making it an attractive option for…
  • 2021 American Transplant Congress

    Tacrolimus Therapeutic Exposure is Not Consistently Predicted by Target Troughs or CYP3A5 Variants in Stable Renal Transplant Recipients

    K. Tornatore1, K. Attwood2, D. Brazeau3, B. Murray4

    1Pharmacy Practice, School of Pharmacy; University at Buffalo, Buffalo, NY, 2Biostatistics, School of Public Health; University at Buffalo, Buffalo, NY, 3Pharmacy Practice, School of Pharmacy; Marshall University, Huntington, WV, 4Medicine, Erie County Medical Center Corp., Buffalo, NY

    *Purpose: Tacrolimus (TAC) immunosuppression requires therapeutic trough monitoring post-transplant due to notable interpatient pharmacokinetic(PK) variability which may be attributed to CYP3A5 polymorphisms. We investigated the…
  • 2021 American Transplant Congress

    Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?

    M. McGowan1, A. Bickenbach1, B. Miyagawa2, A. Christianson1, T. Mizuno2, P. West-Thielke3, J. Leone4, E. Woodle1, D. Kaufman5, A. Wiseman6, A. Matas7, A. Vinks2, R. Alloway1

    1U Cincinnati, Cincinnati, OH, 2Cincinnati Children's Med Center, Cincinnati, OH, 3U Illinois, Chicago, IL, 4Tampa Gen, Tampa, FL, 5U Wisconsin, Madison, OH, 6Centura Transplant, Denver, CO, 7U Minnesota, Minneapolis, MN

    *Purpose: Phase 1 and 2 belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies. PK data from these studies revealed higher BELA troughs on Day…
  • 2021 American Transplant Congress

    Evaluation of Conversion to Extended-Release Tacrolimus in Abdominal Organ and Thoracic Transplant Recipients

    A. Diamond1, N. Agarwal2, A. Younas2, N. Sifontis2, J. Au1, C. Ruggia-Check1

    1Pharmacy, Temple University Hospital, Philadelphia, PA, 2Pharmacy, Temple University School of Pharmacy, Philadelphia, PA

    *Purpose: An established approach for conversion from immediate-release tacrolimus (IR TAC) to extended-release tacrolimus (LCPT) in kidney transplantation exists, but is lacking in other organ…
  • 2020 American Transplant Congress

    Relationship between Tacrolimus Intrapatient Variability and Medication Adherence in Kidney Transplant Recipients

    A. D. Leino, K. Abuls, J. L. Rodgers, K. Kuntz

    The Ohio State University Wexner Medical Center, Columbus, OH

    *Purpose: Intrapatient variability (IPV) has been established as a risk factor for poor post-transplant outcomes. IPV is frequently proposed to be related to nonadherence but…
  • 2020 American Transplant Congress

    Basiliximab Induction in the Obese: One Size Does Fit All

    A. D. Reticker1, D. Choi1, A. B. Lichvar1, C. Kane2, I. Tzvetanov3, E. Benedetti3, J. J. Benken1

    1Pharmacy Practice, University of Illinois Hospital and Health Sciences System, Chicago, IL, 2Pharmacy, Northwestern Memorial Hospital, Chicago, IL, 3Surgery, University of Illinois Hospital and Health Sciences System, Chicago, IL

    *Purpose: Surgical advancements allow more obese (BMI> 30 kg/m2) patients to receive a renal transplant. The original clinical and pharmacokinetic (PK) trials in transplantation immunosuppression…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences